Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go:
Stretch
investment:
Withheld
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
Husky is the UK’s only open, SaaS platform for workplace pensions. For employers, the platform deals with legal and compliance burdens of auto-enrolment while helping reduce pension costs. For individuals and company directors, the app is instrumental in bringing profitable and responsible investments with the Husky for Everyone app. And for advisers and accountants, it ensures strong client relationships amidst transparency and efficiency. Close to 1.4 million employers & 22.6 million workers are affected by the UK’s automatic enrolment (AE) legislation. Within this market, a conservative estimate of fees charged on employees by pension providers is £2 billion a year; Husky aims to disrupt this market & is ready to scale. Its method of operation has led to it achieving important milestones. With more than 1000 firms onboarded, a 92% renewal rate, and an average annual fee of £438, Husky charges its onboarded firms (including Crowdcube) with monthly recurring fees laid out as part of a 3-year subscription model. With the funds received, the company aims to disrupt the relatively stagnant workplace pensions industry with innovative products and empower its customers.
days to go:
Expired
investment:
£417,338
Billon have created a technology that enables zero cost global payments by the use of a simple mobile app. Billon's mobile app allows you to instantly pay for the rest of an article from the Guardian or even donate to your favourite Youtubers with a few clicks of a button.
days to go:
Expired
investment:
£1,406,667
Felcana is a patented Eco-system of connected devices: Helix, Home Hub, Micro-Location Beacons and the Felcana application which work together to monitor the pet's (cat or dogs) well-being. This Digital Pet Health Platform tracks pet's behaviour and provides the vet, rich data leading to faster diagnosis and faster treatment. Felcana has been developed by a world-class team of vets and engineers and, it has been designed and tested by using the latest materials, designs, and techniques. Felcana has won the Design Spark Award in 2017. It is making unique partnerships with leading pet industries and the UK's largest pet health plan provider, the world's top-ranked vet school and The Royal Veterinary College. The new investment will enable it to grow consumer reach and accelerate its sales.
days to go:
Expired
investment:
£343,926
Chip is one of the fastest-growing Fintech companies in the UK. Chip has built an app that uses the user's banking app to make personalised decisions about their money. Its user base has doubled since its previous fundraising in 2018. The company has 153,000 accounts, and it has processed more than £130m of savings. ChipX is the company's revolutionary returns platform and it has a waiting list of more than 50,000 people. The company is a winner of the British Bank Award, 2 Crowdcube awards, and 1 World Banking Award. It has welcomed many management executives from Funding Circle, Monzo, and Purple Bricks. Chip is now scaling with market-leading returns on ChipX. It aims to build the biggest savings account in the world. With the proceeds, the company will double its team and expand ChipX in the €10 trillion European savings market.
days to go:
Expired
investment:
£3,768,260
Easily understand and manage all your insurance in one simple app, ready for the digital age. Wrisk is all about transparency and allows customers to see how much they’re currently paying for their insurance, what actions they can take to reduce their risk and purchase the insurance seamlessly from within the app. Wrisk is seeking investment to expand and cater for as many insurance needs as possible.
days to go:
Expired
investment:
£1,044,630
Baanx is a B2B2C mobile banking platform offering cutting-edge services in remittance, spending & blockchain. The company takes pride in its innovative customer acquisition process through partner communities. The BaanxCL already has a CL™ VISA Debit Card, Crypto-Payment Gateway, a Crypto-Exchange, Stablecoins, and other exciting features. The company is also partnering with new brands around the world which are not banking already but have large user communities to connect. The company is aiming to target 100,000 users by Q2 2020 with the assistance of Super Seed Investors. With the proceeds, Baanx will hire additional team members, spend funds on marketing, and launch services in South America and Asia.
days to go:
Expired
investment:
£658,200
